Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update

(2020) Kimberly H. Allison et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice

(2019) Julia Weber et al.   Nature Communications

Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy

(2018) Alessandra Landmann et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Sensitive and powerful single-cell RNA sequencing using mcSCRB-seq

(2018) Johannes W. Bagnoli et al.   Nature Communications

zUMIs - A fast and flexible pipeline to process RNA sequencing data with UMIs

(2018) Swati Parekh et al.   GigaScience

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

(2016) Michael Untch et al.   LANCET ONCOLOGY

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) E. Senkus et al.   ANNALS OF ONCOLOGY

Low ER+ Breast Cancer

(2014) Nika C. Gloyeske et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Which threshold for ER positivity? a retrospective study based on 9639 patients

(2014) M. Yi et al.   ANNALS OF ONCOLOGY

A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors

(2014) Jyothi S. Prabhu et al.   Journal of Cancer

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

(2012) Brenda Deyarmin et al.   ANNALS OF SURGICAL ONCOLOGY

The sva package for removing batch effects and other unwanted variation in high-throughput experiments

(2012) Jeffrey T. Leek et al.   BIOINFORMATICS

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

(2012) Takayuki Iwamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY